glioma
Denovo, Anova Begin Brain Cancer Gene Therapy Trial Involving Response Biomarker
In an earlier study, patients with biomarker-positive high-grade glioma lived longer after treatment with DB107 than biomarker-negative patients.
Foundation Medicine Assay Nabs FDA Approval as CDx for Ojemda in Pediatric Patients
The FoundationOne test can be used to identify patients with relapsed or refractory BRAF-altered pediatric low-grade glioma who may be eligible for therapeutic options.
Candel Therapeutics to Raise $80M in Public Stock and Warrants Offering
The firm plans to put the funds toward a biologics licensing application for its lead product candidate CAN-2409 in prostate cancer.
Pathos AI Closes $62M Series C Funding Round
The financing will allow the firm to further develop its AI platform, develop drugs in best responders, and acquire new pipeline candidates.
FDA Approves Thermo Fisher Oncomine Dx Target Test as CDx for Servier's Voranigo Brain Cancer Drug
The approval expands the clinical indications for the test, which was previously approved as a CDx for non-small cell lung cancer, thyroid cancer, and bile duct cancer drugs.